Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials.

Network meta-analysis of randomised controlled trials

“DesignNetwork meta-analysis of randomised controlled trials.”

Adults with overweight or obesity without diabetes

“To compare the efficacy and safety of glucagon-like peptide 1 (GLP-1) based drug treatments for weight loss in adults with overweight or obesity without diabetes.”

58 trials involving 24,214 participants

“58 trials of 24 214 participants were analysed.”

Intervention durations ranging from 12 to 104 weeks

“The included trials evaluated various GLP-1 receptor agonists against placebo or active comparators, with intervention durations ranging from 12 to 104 weeks.”

Next generation incretin based treatments achieved greater weight loss than conventional GLP-1 receptor agonists

“In adults with overweight or obesity without diabetes, next generation incretin based treatments achieved greater weight loss than conventional GLP-1 receptor agonists.”